DDInter1293 DDInter915
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Nilotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Nilotinib {u} (Compound) upregulates {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Nilotinib {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Nilotinib {u} (Compound) upregulates {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Nilotinib {u} (Compound) upregulates {v} (Gene) ICAM1
ICAM1 {u} (Gene) is upregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Nilotinib {u} (Compound) upregulates {v} (Gene) ADRB2
ADRB2 {u} (Gene) is associated with {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Nilotinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) EPHA3
EPHA3 {u} (Gene) is upregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Nilotinib {u} (Compound) upregulates {v} (Gene) ICAM1
ICAM1 {u} (Gene) regulates {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Nilotinib {u} (Compound) upregulates {v} (Gene) DHDDS
DHDDS {u} (Gene) is regulated by {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Nilotinib {u} (Compound) downregulates {v} (Gene) CDC25B
CDC25B {u} (Gene) is downregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Nilotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Nilotinib (Compound) upregulates ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)
Nilotinib (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Nilotinib (Compound) upregulates ADRB2 (Gene) and ADRB2 (Gene) is bound by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Nilotinib (Compound) upregulates ICAM1 (Gene) and ICAM1 (Gene) is upregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Nilotinib (Compound) upregulates ADRB2 (Gene) and ADRB2 (Gene) is associated with asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Nilotinib (Compound) binds EPHA3 (Gene) and Nilotinib (Compound) upregulates EPHA3 (Gene) and EPHA3 (Gene) is upregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Nilotinib (Compound) upregulates ICAM1 (Gene) and ICAM1 (Gene) regulates ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)
Nilotinib (Compound) upregulates DHDDS (Gene) and DHDDS (Gene) is regulated by ABCB1 (Gene) and ABCB1 (Gene) is bound by Indacaterol (Compound)
Nilotinib (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)